BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET APPLICATION

生物测试设施 - 避孕目标应用

• 批准号: 10576708
• 负责人: DEBORAH BUNIN
• 金额: $ 22.9万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-17 至 2022-11-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576708
• 关键词: Area; Bioinformatics; Biological Testing; Clinical; Clinical Trials; Collaborations; Contraceptive Agents; Contraceptive Availability; Contraceptive Devices; Data; Databases; Development; Devices; Drug Formulations; Evaluation; In Vitro; Internet; Investigational New Drug Application; Knowledge; Maintenance; Pharmaceutical Preparations; Phase; Preparation; Process; Research Personnel; Safety; System; Toxicology; Update; Work; contraceptive target; design; drug discovery; drug testing; efficacy evaluation; in vivo; next generation; novel; novel strategies; pre-clinical; reproductive; stability testing; user-friendly; web app; web site

Early phase non-steroidal contraceptive discovery and development is limited by known targets and readily accessibility of this information. It is important to facilitate the discovery, curation and availability of contraceptive targets with the aim of developing new approaches to advance next generation of safe contraceptive drug/device. To alleviate this obstacle, bioinformatics driven approach to identify and curate those targets from the existing databases was established. To further allow easy accessibility and friendly user interface for this database, a web application is needed. The Biological Testing Facility has bioinformatics and web design and application capability to achieve this task, in addition to permit rapid evaluation (in vitro and in vivo) of new compositions of matter to the target, efficacy evaluation, safety/ toxicology assessment, drug formulations, delivery systems, and devices for contraceptives followed by clinical batch preparation/ release and continued stability testing of drugs to be evaluated in clinical trials. The BTF provides overall project management and the capabilities to support all phases of novel target product identification, drug discovery/ optimization, preclinical activities and development of contraceptives and associated tasks leading to the filing of investigational new drug (IND) applications.

早期非甾体避孕药的发现和开发受到已知靶点的限制 并且容易获得这些信息。重要的是要促进发现， 目的是制定新的办法， 下一代安全避孕药物/装置。为了缓解这一障碍，生物信息学驱动 确定了从现有数据库中确定和管理这些目标的方法。到 进一步允许该数据库的容易访问性和友好的用户界面， needed.生物试验设施有生物信息学和网页设计和应用 实现这一任务的能力，除了允许快速评价（体外和体内）新的 靶向物质组成、疗效评价、安全性/毒理学评价、药物 用于避孕药的制剂、递送系统和装置，随后进行临床批量生产 制备/释放和持续稳定性测试的药物进行临床试验中评估。的 BTF提供全面的项目管理和支持新目标所有阶段的能力 产品鉴定、药物发现/优化、临床前活动和开发 避孕药和导致研究性新药（IND）备案的相关任务 应用.